# Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

> **NCT00688116** · PHASE1 · UNKNOWN · sponsor: **Synta Pharmaceuticals Corp.** · enrollment: 45 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** STA 9090 (ganetespib)

## Key facts

- **NCT ID:** NCT00688116
- **Lead sponsor:** Synta Pharmaceuticals Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-10
- **Primary completion:** 2014-04
- **Final completion:** 2014-11
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2014-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00688116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00688116, "Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00688116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*